Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough

被引:228
作者
Lang, AE
Obeso, JA
机构
[1] Univ Toronto, Toronto Western Hosp, Movement Disorder Clin, Toronto, ON M5T 2S8, Canada
[2] Univ Navarra, Sch Med, E-31080 Pamplona, Spain
[3] Clin Univ, Dept Neurol Neurosci, E-31080 Pamplona, Spain
关键词
D O I
10.1016/S1474-4422(04)00740-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Levodopa remains the most effective treatment for Parkinson's disease (PD). However, the drug is complicated by a wide range of adverse effects, most notably motor fluctuations and dyskinesias. Long-acting dopamine agonists are associated with a reduced incidence of these complications and modem surgical approaches and pharmacological methods of providing more continuous dopaminergic stimulation have a substantial ameliorative effect on these problems. Despite these advances, disease progression remains unaffected. For this reason there has been much enthusiasm for cellular therapies designed to replace degenerating nigrostriatal dopaminergic neurons. However, recent fetal transplant trials have failed to show expected benefit and have been complicated by "off medication dyskinesias". Even if successful, such treatment may be predestined to provide no better outcome than available treatments given current medical and surgical experience that emphasises the increasingly critical role of "non-dopaminergic" symptoms to quality of life in late-stage PD. Knowledge of the widespread, multisystem nature of the neurodegeneration that accounts for these problems suggests that restoration of the nigrostriatal dopamine system should not be the ultimate goal of future research.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 82 条
[1]   Risk of dementia in Parkinson's disease - A community-based, prospective study [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Lolk, A ;
Nielsen, H ;
Kragh-Sorensen, P .
NEUROLOGY, 2001, 56 (06) :730-736
[2]   HYPERACTIVITY OF REMAINING DOPAMINERGIC NEURONS AFTER PARTIAL DESTRUCTION OF NIGRO-STRIATAL DOPAMINERGIC SYSTEM IN RAT [J].
AGID, Y ;
JAVOY, F ;
GLOWINSKI, J .
NATURE-NEW BIOLOGY, 1973, 245 (144) :150-151
[3]  
Agid Y., 1987, MOVEMENT DISORD, V2, P166
[4]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[5]   Stem cells in the treatment of Parkinson's disease [J].
Arenas, E .
BRAIN RESEARCH BULLETIN, 2002, 57 (06) :795-808
[6]  
BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5
[7]   Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease [J].
Bezard, E ;
Dovero, S ;
Prunier, C ;
Ravenscroft, P ;
Chalon, S ;
Guilloteau, D ;
Crossman, AR ;
Bioulac, B ;
Brotchie, JM ;
Gross, CE .
JOURNAL OF NEUROSCIENCE, 2001, 21 (17) :6853-6861
[8]   Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys [J].
Bezard, E ;
Ravenscroft, P ;
Gross, CE ;
Crossman, AR ;
Brotchie, JM .
NEUROBIOLOGY OF DISEASE, 2001, 8 (02) :343-350
[9]   Neural transplantation for the treatment of Parkinson's disease [J].
Björklund, A ;
Dunnett, SB ;
Brundin, P ;
Stoessl, AJ ;
Freed, CR ;
Breeze, RE ;
Levivier, M ;
Peschanski, M ;
Studer, L ;
Barker, R .
LANCET NEUROLOGY, 2003, 2 (07) :437-445
[10]   Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model [J].
Björklund, LM ;
Sánchez-Pernaute, R ;
Chung, SM ;
Andersson, T ;
Chen, IYC ;
McNaught, KS ;
Brownell, AL ;
Jenkins, BG ;
Wahlestedt, C ;
Kim, KS ;
Isacson, O .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (04) :2344-2349